the aid library

LIST OPTIONS

Filter

894

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (241)

View PDF (252)

Start Free Stay Free AIDS Free (2017 progress report)

UNAIDS; Unicef; World Health Organization; et al. UNAIDS; Unicef; World Health Organization; et al. (2017) C2

Download (1375)

View PDF (3253)

Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India + Annexures

Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare (2012) C1

Download (324)

View PDF (268)

Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy

World Health Organization WHO (2022) C_WHO

WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi... more

Download (1386)

View PDF (2361)

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Prof. G. N. Lule, Dr. B. Nyawira Gastroenterology Society of Kenya , Republic of Keny (2015) C1

External Link

Tuberkulosescreening bei asylsuchenden Kindern und Jugendlichen < 15 Jahren in Deutschland

Nicole Ritz, Folke Brinkmann, Cornelia Feiterna-Sperling. et al. Springer (2015) C2

Stellungnahme der Arbeitsgruppe AWMFLeitlinie Tuberkulose im Kindes- und Jugendalter: Diagnostik, Prävention und Therapie unter Federführung der Deutschen Gesellschaft für Pädiatrische Infektiologie. Monatsschr Kinderheilkd 2015 · 163:1287–1292 DOI 10.1007/s00112-015-0007-5 © Deutsche Gesel... more

Download (696)

View PDF (1183)

Tanzania: HIV Care and Treatment Plan 2003-2008

The William J. Clinton Foundation Ministry of Health, Tanzania (2003) C1

Download (363)

View PDF (477)

Tuberculoses à bacilles résistants : diagnostic et prise en charge

Haut Conseil de la Santé Publique (2014) C2

Lignes directrices. Collection Avis et Rapports.

Download (403)

View PDF (553)

Tuberculosis prevention, care and control A practical directory of new advances

Stop TB Partnership; World Health Organization ; USAID (2011) C_WHO

Download (540)

View PDF (867)

Medicinal plants for forest conservation and health care

Bodeker, Gerard (Ed.) Food and Agriculture Organization (FAO) (1997) C1

Non-Wood Forest Products 11 Traditional medicine and its use of medicinal plants is dependent on reliable supply of plant materials. The book focuses on the interface between medicinal plant use and conservation of medicinal plants.

Download (360)

View PDF (556)

Приоритетные аспекты изучения проблемы ТБ/ВИЧ в условиях высокой распространенности ВИЧ-инфекции и ограниченных ресурсов

Delphine Sculier, Haileyesus Getahun, Reuben Granich World Health Organization, TB HIV working group, Stop TB Partnership (2011) C_WHO

Цель этого документа – повысить уровень осознания актуальности приоритетных направлений научных исследований по проблеме ТБ/ВИЧ (то есть по тем направлениям, кот... more

Download (454)

View PDF (493)

DHR-ICMR GUIDELINES FOR DIAGNOSIS AND MANAGEMENT OF RICKETTSIAL DISEASES IN INDIA

Indian Council of Medical Research (ICMR) (2015) C1

The present DHR-ICMR guidelines comprehensively address the various concerns regarding the clinical assessment, treatment, and laboratory diagnosis of rickettsial diseases in India and the world. It is hoped that physicians, health care workers, the scientific community, the regulatory agencies, pub... more

Download (326)

View PDF (566)

Health system considerations: when influenza meets COVID-19: preparedness and response measures when COVID-19, influenza and acute respiratory infections coincide in the WHO European Region

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

revised version December 2020

Download (314)

View PDF (342)

Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination

World Health Organization WHO (2022) C_WHO

Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method... more

Download (281)

View PDF (281)

WHO Drug Information - Volume 36, No. 4

World Health Organisation (WHO) (2023) C_WHO

Pharmaceutical News Evaluation of Saccharide Content of the WHO 2nd International Standard for Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP) by HPAECPAD Analysis Following Acid Hydrolysis Consultation Documents Lamivudine and tenofovir disoproxil fumarate tablets (lami... more

External Link

Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever -Revised and expanded edition

World Health Organization WHO Regional Office for South-East Asia WHO Regional Office for South-East Asia (2011) CC

Revised and expanded version of the Guidelines

Download (2442)

View PDF (2935)

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer)
recommended

World Health Organization WHO WHO (2012) C_WHO

Guidance for health workers

External Link

Drug-resistant tuberculosis in Central Mozambique: the role of a rapid genotypic susceptibility testing

Evangelina IN, Inês T, Miguelhete L et al (2016) CC

This study consists of a descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015, being the first report of a genotypic testing used to provide information about second line drug resistance in Mozambique. BMC Infectious Diseases (2016) 16:423 DO... more

Download (2098)

View PDF (4364)

Polio Laboratory Manual

World Health Organization (2004) C_WHO

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya recommended

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer) recommended

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer)
recommended